(Q53258455)

12 May 2018

title

Cerebrospinal fluid markers for prediction of Alzheimer's disease (English)

1 reference

https://api.crossref.org/works/10.1016/J.NEULET.2003.08.011

1 April 2024

0 references

1

Henrik Zetterberg

1 reference

12 May 2018

3

Kaj Blennow

1 reference

12 May 2018

2

Lars-Olof Wahlund

1 reference

12 May 2018

language of work or name

English

0 references

publication date

1 November 2003

1 reference

12 May 2018

27 November 2003

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14615052

full work available at URL

1 April 2024

https://api.elsevier.com/content/article/PII:S0304394003009844?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.NEULET.2003.08.011

https://api.elsevier.com/content/article/PII:S0304394003009844?httpAccept=text/plain

1 April 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEULET.2003.08.011

1 April 2024

1 reference

12 May 2018

volume

352

1 reference

12 May 2018

issue

1

1 reference

12 May 2018

page(s)

67-69

1 reference

12 May 2018

Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.

cites work

2

1 reference

https://api.crossref.org/works/10.1016/J.NEULET.2003.08.011

Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment

1 April 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.NEULET.2003.08.011

Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice

1 April 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.NEULET.2003.08.011

CSF phosphorylated tau protein and mild cognitive impairment: a prospective study.

1 April 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.NEULET.2003.08.011

CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects

1 April 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.NEULET.2003.08.011

1 April 2024

“Mini-mental state”

9

1 reference

https://api.crossref.org/works/10.1016/J.NEULET.2003.08.011

Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease

1 April 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.NEULET.2003.08.011

High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

1 April 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.NEULET.2003.08.011

Uses and abuses of screening tests

1 April 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.NEULET.2003.08.011

Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF.

1 April 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.NEULET.2003.08.011

Tau protein in cerebrospinal fluid is significantly increased at the earliest clinical stage of Alzheimer disease.

1 April 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.NEULET.2003.08.011

Cerebrospinal protein tau is elevated in early Alzheimer's disease.

1 April 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.NEULET.2003.08.011

Cerebrospinal beta-amyloid ((1-42)) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline.

1 April 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.NEULET.2003.08.011

Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization.

1 April 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.NEULET.2003.08.011

Index for rating diagnostic tests

1 April 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.NEULET.2003.08.011

1 April 2024

Identifiers

1 reference

12 May 2018

1 reference

12 May 2018